Whole Genome Sequencing Informed Patient Personalized Measurable Residual Disease Assays for Acute Myeloid Leukemia

Niveditha Ravindra[1], Justin Lack[2], Clifton L. Dalgard[3], Eddy vanCollenburg[4], Adam Corner[4], Lan Beppu[5], Harry Erba[6], Megan Othus[7], Jerald P. Radich[5,8], Laura W. Dillon[9#], Christopher S. Hourigan[9#]

#CSH and LWD contributed equally to this work

[1]Laboratory of Myeloid Malignancies, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD
[2]Integrated Data Sciences Section, National Institutes of Health, Bethesda, MD
[3]The American Genome Center, Uniformed Services University of the Health Sciences, Bethesda, MD
[4]Bio-Rad Laboratories, Digital Biology Group, 5731, W. Las Positias Blvd, Pleasanton, CA
[5]Translational Science & Therapeutics Division, Fred Hutchinson Cancer Center, Seattle, WA
[6]Duke University School of Medicine, Durham, NC
[7]Public Health Sciences Division, Fred Hutchinson Cancer Center, Seattle, WA
[8]Division of Medical Oncology, Department of Medicine, University of Washington, Seattle, WA
[9]Fralin Biomedical Research Institute, Virginia Tech FBRI Cancer Research Center, Washington, DC

Main Text: 1418 Words
Figures: 1
Tables: 1
References: 15

Corresponding Authors:
Laura W. Dillon, PhD, FACMG
Fralin Biomedical Research Institute
Virginia Tech FBRI Cancer Research Center
7144 13th Place NW, Washington, D.C. 20012
Email: ldillon@vtc.vt.edu

Christopher S. Hourigan DM DPhil FRCP
Fralin Biomedical Research Institute
Virginia Tech FBRI Cancer Research Center
7144 13th Place NW, Washington, D.C. 20012
Email: hourigan@vt.edu

Acknowledgments and Funding

This work was funded, in part, by the Intramural Research Program of the National Heart, Lung, and Blood Institute (NHLBI). Sequencing was performed at the American Genome Center, Uniformed Services University of the Health Sciences. Digital droplet PCR experiments were performed with the support of the Center for Cancer Research Genomics core at the National Cancer Institute. Support for the FNIH Biomarkers Consortium MRD in AML (Measurable Residual Disease in Acute Myeloid Leukemia) project was provided by AbbVie; Amgen; AstraZeneca; Genentech, a member of the Roche Group; Gilead Sciences, Inc.; GSK; Jazz Pharmaceuticals, Inc.; LGC Clinical Diagnostics, Inc.; Novartis; Syndax Pharmaceuticals, Inc.; Sysmex Corportation. In-kind donations of standards and methods materials and equipment to support the project were provided to the FNIH by AccuGenomics, Inc.; Bio-Rad Laboratories, Inc.; Invivoscribe, Inc.; LGC Clinical Diagnostics, Inc.; Mission Bio; 10x Genomics, Inc.;

Takeda Pharmaceuticals U.S.A., Inc.; Thermo Fisher Scientific Inc.; TwinStrand Biosciences, Inc.; Twist Bioscience Corporation.

The views expressed in this article do not reflect the official policy or position of the National Institute of Health, the Department of the Navy, the Department of Defense, Health Resources and Services Administration (HRSA) or any other agency of the U.S. Government.

Competing Interests

Research at the Laboratory of Myeloid Malignancies was supported by the NHLBI through funding from the Foundation of the NIH AML Biomarkers Consortium. CH has received research support from the Foundation of the NIH Biomarkers Consortium and Illumina, travel support from Invivoscribe, and served on advisory boards for Astellas, Bio-Rad, Janssen and Syndax. AC and EvC are employees and shareholders at Bio-Rad Laboratories. LWD has received honoraria from Bio-Rad Laboratories and travel support from Invivoscribe. HE has received contract research support from Agios, ALX Oncology, Aptose, Ascentage, Daiichi Sankyo, Gilead, Immunogen, Kura Oncology, MacroGenics, Novartis, Oryzon, Sumitomo, Taiho Oncology; consultant for AbbVie, Astra Zeneca, Daiichi Sankyo, Glycomimetics, Kura Oncology, Schrodinger, Servier, Stemline, Sumitomo Pharmaceuticals, Taiho Oncology; speaker bureau for AbbVie, Incyte, Jazz, Servier, Syndax. All other authors report no relevant conflicts of interest.

Abstract

Post-treatment measurable residual disease (MRD) in acute myeloid leukemia (AML) patients is associated with adverse clinical outcomes. Validated molecular methods for AML MRD are preferable to flow cytometry assays but are not available for all patients. The limit of detection (LOD) of next-generation sequencing (NGS) assays for single nucleotide variants is restricted by technical error rates. Structural alterations are common genetic features of AML, but MRD approaches for detecting this class of variants have primarily relied on RNA. However, RNA has suboptimal stability, not all structural alterations are expressed as transcripts, and the impact of anti-leukemic therapy on transcription may make leukemic disease burden quantification inaccurate. In this study, we demonstrate a whole genome sequencing (WGS)-based approach to identify genomic DNA breakpoints of chromosomal rearrangements that allowed design of highly sensitive patient-personalized digital droplet PCR (ddPCR) MRD assays.

Acute myeloid leukemia (AML) is an aggressive malignancy of the hematopoietic precursor cells that predominantly affects older individuals. Oncogenic transformation occurring through the acquisition of structural chromosomal aberrations is noted in 35% of AML cases, and can result in the formation of fusion proteins that confer proliferation and survival advantages (1). When compared to classical cytogenetics for the identification of structural variants at diagnosis, newer techniques such as optical genome mapping can identify clinically pertinent aberrations that may be cryptic or smaller than the resolution of conventional karyotyping and FISH (2). Similarly, short-read whole genome sequencing (WGS) has been shown to increase diagnostic yield and better refine risk stratification when compared to traditional cytogenetic testing in

myeloid malignancies (3). Additionally, WGS can be utilized to identify genomic breakpoints of chromosomal rearrangements at a basepair (bp) resolution.

Main Text

The presence of measurable residual disease (MRD) in complete remission (CR) is prognostic of outcomes in patients with AML (4) and validated molecular methods for MRD monitoring are preferable to flow cytometry assays but are not available for all patients (5). The limit of detection (LOD) of next-generation sequencing (NGS) assays for single nucleotide variants is restricted by technical error rates and not all patients have a molecular variant detectable by standard NGS assays. Structural alterations are common genetic features of AML, but MRD approaches for detecting this class of variants have primarily relied on RNA. However, RNA has suboptimal stability, not all structural alterations are expressed as transcripts, and the impact of anti-leukemic therapy on transcription may make leukemic disease burden quantification inaccurate. These shortcomings could largely be overcome by using DNA-based assays which provide accurate quantification of MRD and prevent contamination, although breakpoints are widely distributed in intronic regions (6). In this study, we describe a sensitive DNA-based patient-personalized approach to MRD detection in AML by droplet digital PCR (ddPCR) using breakpoint information from WGS.

Bone marrow (BM) or peripheral blood samples from 62 adult patients with AML enrolled on the randomized Phase 3 SWOG-S0106 trial (NCT00085709) were previously assessed by our group for MRD in first CR by multiparametric flow cytometry (MFC) and duplex sequencing (DS)

(7). While MRD detection by DS was highly predictive of adverse outcomes and strongly outperformed MFC, it did not predict relapse in all cases and 8% of patients did not have an appropriate variant available for monitoring. Therefore, we sought to investigate if WGS-informed MRD tracking of structural alterations could overcome this limitation by selecting 5 patients from this cohort who experienced relapse and had known cytogenetic abnormalities detected at diagnosis (**Table 1**), consisting of 2 patients without a DS-trackable variant and 3 patients with DS-trackable variants (*FLT3*, *NRAS,* and *KIT*). Among selected patients with trackable variants, there were 2 false negatives and 1 true positive for MRD by DS. The Institutional Review Board of the Fred Hutchinson Cancer Center gave ethical approval for this work, and patients were treated according to the Declaration of Helsinki. Full details on experimental methods are outlined in the supplement.

Initially, we performed a proof of concept experiment by designing a ddPCR assay for the genomic *CBFB::MYH11* breakpoints previously characterized in the ME-1 cell line (8). For all ddPCR analysis performed in this study, protocols suggested by the manufacturer were followed (Bio-Rad Laboratories Inc., Hercules, CA). Briefly, 300-900ng (300ng/reaction) of genomic DNA was combined with ddPCR supermix for probes (no dUTP) (Catalog number: 1863025, Bio-Rad Laboratories Inc., Hercules, CA, USA), HindIII restriction enzyme (Catalog number: R0140S, New England BioLabs Inc., Ipswich, CA, USA), and mutant and reference gene primers and probes at a final concentration of 900 nM and 250 nM, respectively. This was followed by droplet generation, PCR, droplet reading, and data analysis using the QuantaSoft software. Serial dilution of ME-1 cell line DNA into healthy donor DNA (range 5%-0.001%) established the LOD

of the cell line-specific *CBFB::MYH11* assay as 0.001% variant allele frequency (VAF), with high sensitivity, no background noise, and high correlation to the expected VAF (r^2=0.99, P<0.0001) (**Supplementary Figure 1**).

For the 5 AML patients, WGS libraries were constructed from baseline BM DNA using the TruSeq DNA PCR-free library preparation kit (Illumina, San Diego, California, USA) and subjected to 150-bp paired-end WGS to an average depth of 65X on the NovaSeq 6000 platform (Illumina) according to the manufacturer's protocols. The analytic pipeline for structural variants (SVs) and copy-number changes (CNVs) was modified from the Chromoseq pipeline described by Duncavage *et al* (3). Specifically, this workflow flags and retains recurrent and risk-defining SVs and CNVs while more stringent filtering criteria are applied to novel variants. The workflow of the study has been outlined in **Figure 1A**.

WGS successfully identified the genomic DNA breakpoints of all anticipated chromosomal rearrangements in the 5 diagnostic AML samples (**Table 1**). In one patient (J9-11568), WGS was able to resolve an unclear cytogenetic finding on the q arm of chromosome (chr) 7 as a derivative chr resulting from a translocation between chr 7 and 11, der(7)t(7;11)(q31.1;q22.1), resulting in a 50Mb net loss of material on 7q31.1-q36.3 and 35Mb gain of material on 11q22.1-q25. In a second patient (J9-11569), WGS identified a 2Mb deletion on 11q23.3. In both cases, the patient had core-binding factor AML harboring inv(16), and the identification of secondary cytogenetic abnormalities within this disease class has been linked to distinct prognostic impacts depending on the abnormalities identified (9).

One structural event was selected per patient and the breakpoints were confirmed by Sanger sequencing, including *CBFB::MYH11* (n=3), *RUNX1::RUNX1T1* (n=1), and *DEK::NUP214* (n=1) **(Table 1, Supplementary Table 1).** Custom FAM-tagged ddPCR assays targeting the translocation event were designed for each patient and multiplexed with a HEX-tagged *EIF2C1* reference gene assay (Bio-Rad Laboratories Inc., Hercules, CA, assay ID: dHsaCP1000002) for calculation of wild-type genome copies. Individual assays were validated using 900ng of input DNA by serial dilution experiments (range 1%-0.0001%), establishing LODs ranging from 0.01%-0.001% VAF **(Figure 1B).**

Patient-personalized assays were subsequently tested on post-treatment remission BM samples and identified MRD positivity in all 5 patients who relapsed, with VAFs ranging from 0.0016%-0.016% (**Table 1**). This contrasted with DS, which predicted relapse in a single patient, and MFC which was negative for MRD in all patients. Patient J9-11578, who was MRD positive by both molecular methods had similar residual disease levels by each technique, with a VAF of 0.016% for the *DEK::NUP214* translocation by WGS-informed ddPCR and 0.011% for *FLT3*-ITD by DS. The remaining two patients with DS-trackable variants had residual SV VAFs of 0.0016% and 0.0022% for the *CBFB::MYH11* and *RUNX1::RUNX1T1* fusions, respectively.

This study demonstrates a sensitive, patient-personalized strategy for AML MRD detection for chromosomal structural variants that uses breakpoint information from WGS and DNA as the analyte. This approach was able to successfully predict relapse in all remission samples in the

small cohort of patients tested and highlights the sensitivity and specificity of targeting unique chromosomal breakpoints as compared to other more technically error-prone variants such as SNVs. When comparing RNA- and DNA-based methods for AML MRD detection for common fusions, Lukes *et al* showed that genomic DNA-based assays were more sensitive than RNA-based assays, and low transcript levels at diagnosis significantly affected MRD detection using RNA at later time points (10). In another study performed on a cohort of pediatric AML patients, genomic MRD positivity at day 28 was the only significant predictor for overall and event-free survival by multivariate analysis (11). Both studies used targeted next generation (NGS) with custom probes capturing the fusions of interest. However, WGS can provide additional information regarding the diagnostic karyotype, such as chromosomal gains and losses in addition to genomic breakpoints. Moreover, copy number changes such as deletions of important tumor suppressor genes and passenger variants can also be potential MRD targets, which will require future investigation. MRD detection by NGS is gaining wider acceptance, especially for *FLT3*-ITD and *NPM1* which are highly prognostic for relapse (12), and it would be reasonable to spike-in primers/probes targeting SVs into multigene NGS panels.

While WGS-based MRD monitoring offers several benefits, the major factors limiting its use in clinical laboratories would be the cost and expertise required to implement bioinformatics workflows, interpretation of results, and the regulatory burden of validating patient-specific assays. Furthermore, given the sensitivity of WGS (13, 14), tumor cell enrichment in AMLs with low blast percentages and/or deep WGS may be required. While the workflow described in this study requires more extensive validation in larger patient cohorts to establish clinical utility and

predictive MRD levels, it provides the opportunity to expand applicability of MRD testing to all

AML patients.

References

1. Martens JHA, Stunnenberg HG. The molecular signature of oncofusion proteins in acute myeloid leukemia. FEBS Letters. 2010;584(12):2662-2669. doi:https://doi.org/10.1016/j.febslet.2010.04.002.

2. Levy B, Baughn LB, Akkari Y, Chartrand S, LaBarge B, Claxton D, Lennon PA, Cujar C, Kolhe R, Kroeger K, Pitel B, Sahajpal N, Sathanoori M, Vlad G, Zhang L, Fang M, Kanagal-Shamanna R, Broach JR. Optical genome mapping in acute myeloid leukemia: a multicenter evaluation. Blood Advances. 2023;7(7):1297-1307. doi:10.1182/bloodadvances.2022007583.

3. Duncavage EJ, Schroeder MC, O'Laughlin M, Wilson R, MacMillan S, Bohannon A, Kruchowski S, Garza J, Du F, Hughes AEO, Robinson J, Hughes E, Heath SE, Baty JD, Neidich J, Christopher MJ, Jacoby MA, Uy GL, Fulton RS, Miller CA, Payton JE, Link DC, Walter MJ, Westervelt P, DiPersio JF, Ley TJ, Spencer DH. Genome Sequencing as an Alternative to Cytogenetic Analysis in Myeloid Cancers. New England Journal of Medicine. 2021 2021/03/11;384(10):924-935. doi:10.1056/NEJMoa2024534.

4. Parkin B, Londono-Joshi A, Kang Q, Tewari M, Rhim AD, Malek SN. Ultrasensitive mutation detection identifies rare residual cells causing acute myelogenous leukemia relapse. J Clin Invest. 2017 Sep 1;127(9):3484-3495. Conflict of interest: The authors have declared that no conflict of interest exists. Epub 20170821. doi:10.1172/JCI91964. Cited in: Pubmed; PMID 28825596.

5. Ghannam J, Dillon LW, Hourigan CS. Next-generation sequencing for measurable residual disease detection in acute myeloid leukaemia. Br J Haematol. 2020 Jan;188(1):77-85. Epub 20191205. doi:10.1111/bjh.16362. Cited in: Pubmed; PMID 31804716.

6. Selim AG, Moore AS. Molecular Minimal Residual Disease Monitoring in Acute Myeloid Leukemia: Challenges and Future Directions. The Journal of Molecular Diagnostics. 2018 2018/07/01/;20(4):389-397. doi:https://doi.org/10.1016/j.jmoldx.2018.03.005.

7. Dillon LW, Higgins J, Nasif H, Othus M, Beppu L, Smith TH, Schmidt E, Valentine Iii CC, Salk JJ, Wood BL, Erba HP, Radich JP, Hourigan CS. Quantification of measurable residual disease using duplex sequencing in adults with acute myeloid leukemia. Haematologica. 2023 08/03. doi:10.3324/haematol.2023.283520.

8. van der Reijden BA, Dauwerse HG, Giles RH, Jagmohan-Changur S, Wijmenga C, Liu PP, Smit B, Wessels HW, Beverstock GC, Jotterand-Bellomo M, Martinet D, Mühlematter D, Lafage-Pochitaloff M, Gabert J, Reiffers J, Bilhou-Nabera C, Ommen G-JBv, Hagemeijer A, Breuning MH. Genomic acute myeloid leukemia-associated inv(16)(p13q22) breakpoints are tightly clustered. Oncogene. 1999 1999/01/01;18(2):543-550. doi:10.1038/sj.onc.1202321.

9. Han SY, Mrozek K, Voutsinas J, Wu Q, Morgan EA, Vestergaard H, Ohgami R, Kluin PM, Kristensen TK, Pullarkat S, Moller MB, Schiefer AI, Baughn LB, Kim Y, Czuchlewski D, Hilberink JR, Horny HP, George TI, Dolan M, Ku NK, Arana Yi C, Pullarkat V, Kohlschmidt J, Salhotra A, Soma L, Bloomfield CD, Chen D, Sperr WR, Marcucci G, Cho C, Akin C, Gotlib J, Broesby-Olsen S, Larson M, Linden MA, Deeg HJ, Hoermann G, Perales MA, Hornick JL, Litzow MR, Nakamura R, Weisdorf D, Borthakur G, Huls G, Valent P, Ustun C, Yeung CCS. Secondary cytogenetic abnormalities in core-binding factor AML harboring inv(16) vs t(8;21). Blood Adv. 2021 May 25;5(10):2481-2489. Conflict-of-interest disclosure: The authors declare no competing financial interests. doi:10.1182/bloodadvances.2020003605. Cited in: Pubmed; PMID 34003250.

10. Lukes JJ, Winkowska L, Zwyrtkova M, Starkova J, Sramkova L, Stary J, Trka J, Zuna J, Zaliova M. Identification of Fusion Gene Breakpoints is Feasible and Facilitates Accurate Sensitive Minimal Residual Disease Monitoring on Genomic Level in Patients With PML-RARA, CBFB-MYH11, and RUNX1-RUNX1T1. HemaSphere. 2020;4(6):e489. doi:10.1097/hs9.0000000000000489. Cited in: Pubmed; PMID 02014419-202012000-00014.

11. Zaliova M, Zuna J, Winkowska L, Janotova I, Skorepova J, Lukes J, Meyer C, Marschalek R, Novak Z, Domansky J, Stary J, Sramkova L, Trka J. Genomic DNA-based measurable residual disease monitoring in pediatric acute myeloid leukemia: unselected consecutive cohort study. Leukemia. 2023 2023/11/24. doi:10.1038/s41375-023-02083-9.

12. Dillon LW, Gui G, Page KM, Ravindra N, Wong ZC, Andrew G, Mukherjee D, Zeger SL, El Chaer F, Spellman S, Howard A, Chen K, Auletta J, Devine SM, Jimenez Jimenez AM, De Lima MJG, Litzow MR, Kebriaei P, Saber W, Weisdorf DJ, Hourigan CS. DNA Sequencing to Detect Residual Disease in Adults With Acute Myeloid Leukemia Prior to Hematopoietic Cell Transplant. JAMA. 2023;329(9):745-755. doi:10.1001/jama.2023.1363.

13. Duncavage EJ, Bagg A, Hasserjian RP, DiNardo CD, Godley LA, Iacobucci I, Jaiswal S, Malcovati L, Vannucchi AM, Patel KP, Arber DA, Arcila ME, Bejar R, Berliner N, Borowitz MJ, Branford S, Brown AL, Cargo CA, Döhner H, Falini B, Garcia-Manero G, Haferlach T, Hellström-Lindberg E, Kim AS, Klco JM, Komrokji R, Lee-Cheun Loh M, Loghavi S, Mullighan CG, Ogawa S, Orazi A, Papaemmanuil E, Reiter A, Ross DM, Savona M, Shimamura A, Skoda RC, Solé F, Stone RM, Tefferi A, Walter MJ, Wu D, Ebert BL, Cazzola M. Genomic profiling for clinical decision making in myeloid neoplasms and acute leukemia. Blood. 2022;140(21):2228-2247. doi:10.1182/blood.2022015853.

14. Gong W, Tagliazucchi GM, Comer S, Ghildiyal M, Chavez M, Nobuta K, Dincer TU, Badarinarayan N, Kim G, Bui Q, Davis C, Truong S, Catreux S, O'Connell T, Russell C, Qiu Y, Brundu F, Vashisht A, Mondal A, Spencer D, Kim S, de Feo E, Kolhe R. Analytical Evaluation of Whole Genome Sequencing for Acute Myeloid Leukemia. medRxiv. 2025:2025.10.30.25339095. doi:10.1101/2025.10.30.25339095.

15. ISCN 2020: An International System for Human Cytogenomic Nomenclature (2020). S.Karger AG; 2020 29 Oct 2020. (McGowan-Jordan J, Hastings RJ, Moore S, editors.). ISBN: 978-3-318-06706-4. https://doi.org/10.1159/isbn.978-3-318-06867-2.

Table 1: Comparison of conventional and WGS-based karyotyping at baseline and MRD by duplex sequencing and WGS-informed ddPCR.

Patient	Karyotype	WGS karyotype*	Duplex sequencing MRD targets	MRD result by duplex sequencing, VAF	WGS-informed MRD target	MRD results by WGS-informed ddPCR, VAF
J9-11578	46,XX,t(6;9)(p23;q34)[20]	seq[GRCh38] t(6;9)(p22.3;q34.13) NC_000006.12:g.pter_18226504delins[NC_000009.12:g.131153507_qter] NC_000009.12:g.pter_131153503delins[NC_000006.12:g.18226235_qter]	*FLT3*-ITD	*FLT3*-ITD, 0.011%	t(6;9)(p23;q34) *DEK::NUP214*	Positive, 0.0159%
J9-11574	46,XX,inv(16)(p13.1q22)[17]/ 47,XX,inv(16)(p13.1q22),+22[2]/46,XX[2]	seq[GRCh38] inv(16)(p13.1q22.1) NC_000016.10:g.[15721335_67085250inv;insT]	*NRAS* (Gly12Ser)	Negative	inv(16)(p13.1q22) *CBFB::MYH11*	Positive, 0.0016%
J9-11576	46,XX,t(8;21)(q22;q22)[20]	seq[GRCh38] t(8;21)(q22.12;q21.3) NC_000008.11:g.pter_92066838delins[NC_000021.9:g.34844063_qter] NC_000021.9:g.pter_34844184delins[NC_000008.11:g.92066740_qter]	*KIT* (Asp816Val)	Negative	t(8;21)(q22;q22) *RUNX1::RUNX1T1*	Positive, 0.0022%
J9-11568	46,XY,del(7)(q3?4),inv(16)(p13.1q22)[22]	seq[GRCh38] der(7)t(7;11)(q31.1;q22.1), inv(16)(p13.1q22.1) NC_000016.10:g.[67088239_15721457inv;15721458del] NC_000007.14:g.108403332_qterdelins[GGCCCAGCAGT;NC_000011.10:g.99267776_qter]	No target	Not evaluable	inv(16)(p13.1q22) *CBFB::MYH11*	Positive, 0.0143%
J9-11569	46,XX,inv(16)(p13.1q22)[21]	seq[GRCh38] del(11)(q23.3q23.3),inv(16)(p13.1q22.1) NC_000011.10:g.116763597_118773322del NC_000016.10:g.[15721403_67088894inv]	No target	Not evaluable	inv(16)(p13.1q22) *CBFB::MYH11*	Positive, 0.0040%

*Nomenclature following ISCN 2020 guidelines(15), genomic coordinates correspond to human genome build hg38 WGS; whole genome sequencing, ddPCR; digital droplet PCR, MRD; measurable residual disease, VAF; variant allele frequency; ITD, internal tandem duplication

Figure Legends

Figure 1. Assessment of whole-genome sequencing-informed patient personalized digital PCR assays.
(A) Outline of the study design. (B) Expected versus observed variant allele fraction (VAF) of patient-personalized whole genome sequencing-informed digital PCR assays performed on serial dilutions of positive control DNA. A limit of detection for each assay was achieved ranging anywhere from 0.01%-0.001%.

Figure 1

A

B